Experts: Impact Of HHS/Phlow Partnership On Drug Supply Chain Unclear

Health policy experts say HHS’ move this week to expand drug manufacturing capacity in the United States through a new public-private partnership with Phlow Corporation is a good first step toward ramping up domestic production, but they also caution it’s too soon to tell whether the move will have any real, lasting impact on the overall pharmaceutical supply chain. One expert noted it is unclear how many of the partnership’s facilities and manufacturing components will be based in the United...